Facebook Pixel Pushing The Age Barrier | BioSpectrum Asia - business - Read this story on Magzter.com

Try GOLD - Free

Pushing The Age Barrier

BioSpectrum Asia

|

November 2023

In 2022, 1 in 7 individuals in Asia Pacific were aged 60 or older. This demographic trend is accelerating, with projections suggesting that by 2050, 1 in 4 people in the region will fall into this age group, according to the United Nations, Economic and Social Commission for Asia and the Pacific (ESCAP), 2022.

- Ayesha Siddiqui

Pushing The Age Barrier

To address the growing concern of an ageing population, the APAC region is actively taking steps to tackle longevity-related issues. In August 2023, Singapore marked a significant milestone by inaugurating the world’s very first Healthy Longevity Medicine Clinic. This achievement is part of a broader wave of developments in the region that focuses on the science of ageing and longevity. Let’s explore further.

Asia’s rapid ageing is driving efforts to slow this process, with Singapore at the forefront. In September 2023, a groundbreaking Healthy Longevity Clinic was unveiled at Alexandra Hospital, aimed at delaying biological ageing and enhancing health span. This clinic uses Singapore-specific ageing biomarkers, incorporating research from the NUHS Centre for Healthy Longevity (CHL) to advance precision medicine and geroscience. The CHL, established in September 2022, is a pioneering pre-clinical and clinical ageing research institute, focusing on longevity medicine and biological age. This initiative aligns with Singapore’s broader approach to elderly care outlined in the 2023 Action Plan for Successful Ageing, promoting care, contribution, and connectedness for seniors. In July 2023, Singapore’s Duke-NUS also launched a nationwide study focused on shedding light on the well-being of older individuals and the impact of policies. This comprehensive study is designed to gain a deep understanding of the health, social, and psychological well-being of older citizens. Its ultimate goal is to provide valuable insights that can inform the development of effective policies and programmes to support Singapore’s ageing population.

MORE STORIES FROM BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Asia

Alphamab Oncology appoints Fei Wang as Chief Financial Officer

Hong Kong-based Alphamab Oncology has announced the appointment of Fei Wang as the Chief Financial Officer (CFO).

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

BioSpectrum Asia

CarbGeM inks MoU with DSS Imagetech to expand AI business in Indian market

DSS Imagetech, a leading player in medical and research imaging equipment, has announced the signing of a Memorandum of Understanding (MoU) with Japan-based CarbGeM Inc., a developer of artificial intelligence (AI)-powered life science solutions to expand its AI business in the Indian market.

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

BioSpectrum Asia

PHCbi introduces LiCellGrow Cell Expansion System

PHC Corporation's Biomedical Division, a global provider of laboratory sample storage and cell cultivation solutions and subsidiary of Japan's PHC Holdings Corporation, has announced the launch of its new cell expansion system LiCellGrow for research use in Japan and other select countries worldwide.

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

BioSpectrum Asia

CitiusTech appoints Dhaval Shah as Chief Business Officer - MedTech & Life Sciences

CitiusTech, a leading provider of healthcare technology services driving digital and AI excellence in India, has appointed Dhaval Shah to Chief Business Officer - MedTech & Life Sciences.

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

Thermo Fisher expands immunodiagnostics operations with new distribution centre in Uppsala

Thermo Fisher Scientific Inc. has announced the opening of a new 8,000-square-meter distribution & labeling centre supporting its immunodiagnostics business in Uppsala.

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

BioSpectrum Asia

Harbour BioMed appoints Dr Jenny Xie as Head of Global External Innovation

Harbour BioMed, a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, has announced the appointment of Dr Jenny Xie as Chief Scientific Officer, Immunology and Head of Global External Innovation.

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

BioSpectrum Asia

Argo Biopharma ropes in Dr Gena Wang as CFO and CSO

China-based Argo Biopharmaceutical Co., a clinical-stage biotechnology company committed to developing next-generation siRNA therapies, has announced the appointment of Dr Gena Wang as Chief Financial Officer (CFO) and Chief Strategy Officer (CSO), effective March 1, 2026.

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

IISc launches "Moonshot" project on brain co-processors supported by Pratiksha Trust

The Indian Institute of Science (IISc), Bengaluru has launched an ambitious \"moonshot\" project to develop brain co-processors that combine neuromorphic hardware and artificial intelligence (AI) algorithms to enhance or restore brain function.

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

Korea designs model for accurate and scalable drug-drug interaction prediction

A research team from the School of International Engineering and Science at Jeonbuk National University (JBNU), South Korea, has developed DDINet, a lightweight and scalable model, specifically designed to predict interactions for new, unseen drugs.

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

BioSpectrum Asia

Australia-Singapore study advocates role of intranasal vaccine booster against sarbecoviruses

Researchers at the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine) and Monash University in Australia, have demonstrated that an intranasal vaccine booster may confer significantly stronger and broader immune responses, and provide robust neutralising antibody and resident T cell responses in the lung and nasal tissues, outperforming conventional mRNA booster vaccination.

time to read

1 min

BioSpectrum Asia April 2027

Translate

Share

-
+

Change font size